Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy.

Somatropin with easypod can be cost-saving versus all other r-hGH treatments except Omnitrope when listed drug prices are considered and can be cost-saving versus all other r-hGH treatments when tender drug prices are considered. The easypod device also facilitates cost savings in terms of reduced wastage.